NCT03276078View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2017

Primary Completion Date

June 12, 2018

Study Completion Date

June 12, 2018

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Aclidinium Bromide/Formoterol Fumarate 400/12μg BID

Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days

Trial Locations (1)

130021

Research Site, Changchun